Recurrent Vulvovaginal Candidiasis (RVVC) is a subtype of Vulvovaginal Candidiasis that affects up to 10% of Australian women and has debilitating effects on their physical and emotional wellbeing.1 Current evidence supports the induction and maintenance approach although this long term treatment regime for RVVC is not particularly effective with post-treatment relapse rates as high as 57%.2 An Australian survey of vulval health clinicians identified that a multitude of RVVC management protocols are being utilised in clinical practice nationally,3 and a recent narrative review by our team identified a wide variety of treatment strategies in Australasian RVVC prescribing resources and guidelines.4 Studies assessing the Health-Related Quality of Life (HRQoL) of individuals with RVVC have demonstrated that subjective health status and HRQoL is diminished not only during acute symptom episodes (flare-ups), but also outside of these flare-ups. 1,5 This reduction in HRQoL includes those patients who have received long term maintenance therapy for RVVC.5 The current research will inform patient driven semi-structured interviews. The semi-structured interviews will cover key aspects of RVVC patient experience, comprising of patient knowledge of medical and self-management options, awareness and utilisation of available support services and lifestyle adaptation. Findings from the interviews will be presented and will provide relevance of Patient Orientated Evidence that Matters (POEMS) in designing outcome measures for future clinical trials and qualitative research. Through this research we aim to provide recommendations that could help address inconsistency in design of clinical studies for RVVC management.